

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/684,682	10/04/2000	Gilles H. Tapolsky	359872000810	3633
75	90 07/17/2006		EXAM	INER
A James Nelson Esq Schwegman Lundberg Woessner & Kluth 1600 TCF Tower 121 South Eighth Street Minneapolis, MN 55402			GRAFFEO, MICHEL	
			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 07/17/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office A 41 0	09/684,682	TAPOLSKY ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michel Graffeo	1614				
The MAILING DATE of this communication appearing for Reply	opears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory perior Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION .136(a). In no event, however, may a reply be tind d will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 14.	April 2006.					
	is action is non-final.					
·=	, 					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>19-22,24 and 34-42</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>19-22,24 and 34-42</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/	or election requirement.					
Application Papers	·					
9) The specification is objected to by the Examir	ner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the corre						
11) The oath or declaration is objected to by the E						
Priority under 35 U.S.C. § 119		Trough of format to top.				
	n priority under 25 H.C.C. S. 110(a)	\ (d\ ar (f)				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.						
						 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage
application from the International Burea		ed in this National Stage				
* See the attached detailed Office action for a lis	, , , , , , , , , , , , , , , , , , , ,	ad				
coo and attached detailed office action for a lis	a di mo definica dopies not receive	···				
Attach mant(s)						
Attachment(s)	A) []	(DTO 412)				
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date		atent Application (PTO-152)				

DETAILED ACTION

Status of Action

Claims 19-22, 24 and 34-42 are pending and examined.

Applicant has provided arguments for the patentability of claims 19-22, 24 and 34-42 in the response filed 14 April 2006.

Applicant's arguments, see response, filed 14 April 2006, have been fully considered and are persuasive to the extent that the rejection of claims 19-22, 24 and 34-42 under 35 USC §112 and the rejection of claims 19-22, 24 and 34-40 under 35 USC §102 have been withdrawn. Additionally, the Double Patenting rejections over U. S. Patent No. 6,159,498 and U. S. Patent No. 5,800,832 are withdrawn in light of the approved Terminal Disclaimer. Applicant's request that the Double Patenting rejection over copending Application No. 09/069703 be held in abeyance until it is made permanent is noted but will be maintained in this Office Action and future Office Actions until an appropriate terminal disclaimer is filed and approved.

Any rejection not specifically stated in this Office Action has been withdrawn.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Status of Election/Restriction

To clarify the record, the Restriction Requirement mailed 5 March 2002 and responded to on 15 April 2002 was confirmed by the Examiner in the Office Action mailed 19 August 2002. To that extent, claims 34, 36-39 and 41-42 were properly withdrawn from examination. Thereafter, in the Office Action mailed 12 December 2005 the election requirement was effectively removed and all pending claims were examined. Similarly, pending claims 19-22, 24 and 34-42 are currently being examined.

Claim Rejections - 35 USC § 103

Claims 19-22, 24 and 34-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 4,765,983 to Takayanagi et al. in view of US Patent No. 4,594,240 to Kawata et al.

Takayanagi et al. teach adhesive medical tapes for oral mucosa comprising a support layer composed of an intestine-soluble polymer and a medicament-containing layer composed of a water-soluble polymer containing at least one kind of a steroid or non-steroid antiphlogistic and analgesic medicament (in current claims 19-22, 24 and 34-42; see Abstract), and further comprising a water-soluble polymer such as polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl cellulose (in current claims 22 and 34-40; see col 2 lines 57-end), hydroxypropylmethyl cellulose (claim 36 col 3 line 45) and hydroxymethylethyl cellulose (claim 37 col 3 line 46) and wherein the thickness of the medicament containing layer (which is two layers) is more

than 20µm and at most 300µm (which is equivalent to 0.02-0.3mm: in claim 20 see col 3 lines 5-18).

Kawata et al. teach the use of hydroxyethyl cellulose and polyacrylic acid (in current claims 19, 22, 34 and 38 in particular; see col 2 lines 41-50) in the flexible pharmaceutical containing sheet (see col 1 lines 4-10).

Although neither references specifically teaches the use of the adhesive for a wound or burn site, one of ordinary skill in the art would have found it obvious to use an anti-inflammatory analgesic agent on a site which requires same.

One of ordinary skill in the art would have been motivated to combine the above references and as combined would teach the invention as claimed. One of ordinary skill in the art would have been motivated to combine Takayanagi et al. and Kawata et al. because Takayanagi et al. cite Kawata et al. and further since both are directed to pharmaceutical carrying sheet shaped muco-adhesives. Thus, the combined references teach and make prima facie obvious how to use the claimed invention at the time that it was made.

Response to Arguments - 35 USC §112 and 35 USC §102

Applicant's arguments filed 14 April 2006 have been fully considered and are persuasive for reasons of record.

Art Unit: 1614

Response to Arguments - 35 USC §103

Applicant's arguments filed 14 April 2006 have been fully considered but are not persuasive. Although Kawata et al. may allow for a water-insoluble material, the reference also includes embodiments wherein the product comprises water-soluble materials such as gums and cellulose products. Therefore, as combined the references teach the invention as claimed.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 19-22, 24 and 34-42 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3, 5-6, 15-18 and 33-34 of copending Application No. 09/069703. Although the conflicting

claims are not identical, they are not patentably distinct from each other because the '703 application claims a water-erodible pharmaceutical carrier device comprising a layered flexible film having a first water-erodible adhesive layer to be placed in contact with a mucosal surface, a second, water-erodible non-adhesive backing layer, and a pharmaceutical incorporated with said first layer, said second layer, or both layers, wherein said first water- erodible adhesive layer comprises a film-forming polymer and a bioadhesive polymer, and is free f a plasticizer, and wherein said second water-erodible non-adhesive backing layer comprises hydroxyethyl cellulose and further wherein the total thicknesses of the adhesives overlap.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Application/Control Number: 09/684,682 Page 7

Art Unit: 1614

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michel Graffeo whose telephone number is 571-272-8505. The examiner can normally be reached on 9am to 5:30pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

5 July 2006 MG

> ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER